These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 36821406)

  • 21. Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects.
    Nugent AC; Ballard ED; Gould TD; Park LT; Moaddel R; Brutsche NE; Zarate CA
    Mol Psychiatry; 2019 Jul; 24(7):1040-1052. PubMed ID: 29487402
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression.
    Xu AJ; Niciu MJ; Lundin NB; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Ballard ED; Brutsche NE; Machado-Vieira R; Zarate CA
    Neural Plast; 2015; 2015():858251. PubMed ID: 26137324
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.
    Williams NR; Heifets BD; Blasey C; Sudheimer K; Pannu J; Pankow H; Hawkins J; Birnbaum J; Lyons DM; Rodriguez CI; Schatzberg AF
    Am J Psychiatry; 2018 Dec; 175(12):1205-1215. PubMed ID: 30153752
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Motor-Activity Markers of Circadian Timekeeping Are Related to Ketamine's Rapid Antidepressant Properties.
    Duncan WC; Slonena E; Hejazi NS; Brutsche N; Yu KC; Park L; Ballard ED; Zarate CA
    Biol Psychiatry; 2017 Sep; 82(5):361-369. PubMed ID: 28457485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Slonena EE; Vande Voort JL; Brutsche NE; Zarate CA
    J Clin Psychiatry; 2014 Sep; 75(9):e932-8. PubMed ID: 25295436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Translational control by ketamine and its implications for comorbid cognitive deficits in depressive disorders.
    Lewis V; Rodrigue B; Arsenault E; Zhang M; Taghavi-Abkuh FF; Silva WCC; Myers M; Matta-Camacho E; Aguilar-Valles A
    J Neurochem; 2023 Jul; 166(1):10-23. PubMed ID: 35680556
    [TBL] [Abstract][Full Text] [Related]  

  • 27. P11 (S100A10) as a potential predictor of ketamine response in patients with SSRI-resistant depression.
    Veldman ER; Mamula D; Jiang H; Tiger M; Ekman CJ; Lundberg J; Svenningsson P
    J Affect Disord; 2021 Jul; 290():240-244. PubMed ID: 34010748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine.
    Lundin NB; Niciu MJ; Luckenbaugh DA; Ionescu DF; Richards EM; Vande Voort JL; Brutsche NE; Machado-Vieira R; Zarate CA
    Pharmacopsychiatry; 2014 Jul; 47(4-5):141-4. PubMed ID: 24955551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of Relationship of Ketamine Dose With Magnetic Resonance Spectroscopy of Glx and GABA Responses in Adults With Major Depression: A Randomized Clinical Trial.
    Milak MS; Rashid R; Dong Z; Kegeles LS; Grunebaum MF; Ogden RT; Lin X; Mulhern ST; Suckow RF; Cooper TB; Keilp JG; Mao X; Shungu DC; Mann JJ
    JAMA Netw Open; 2020 Aug; 3(8):e2013211. PubMed ID: 32785636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A review of the kappa opioid receptor system in opioid use.
    Cayir S; Zhornitsky S; Barzegary A; Sotomayor-Carreño E; Sarfo-Ansah W; Funaro MC; Matuskey D; Angarita G
    Neurosci Biobehav Rev; 2024 Jul; 162():105713. PubMed ID: 38733895
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neurocognitive effects of repeated ketamine infusions in comorbid posttraumatic stress disorder and major depressive disorder.
    Albott CS; Lim KO; Erbes C; Thuras P; Wels J; Tye SJ; Shiroma PR
    J Affect Disord; 2022 Jul; 308():289-297. PubMed ID: 35429529
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration.
    Moaddel R; Zanos P; Farmer CA; Kadriu B; Morris PJ; Lovett J; Acevedo-Diaz EE; Cavanaugh GW; Yuan P; Yavi M; Thomas CJ; Park LT; Ferrucci L; Gould TD; Zarate CA
    Transl Psychiatry; 2022 May; 12(1):179. PubMed ID: 35501309
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.
    McCloud TL; Caddy C; Jochim J; Rendell JM; Diamond PR; Shuttleworth C; Brett D; Amit BH; McShane R; Hamadi L; Hawton K; Cipriani A
    Cochrane Database Syst Rev; 2015 Sep; (9):CD011611. PubMed ID: 26415966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals.
    Mkrtchian A; Evans JW; Kraus C; Yuan P; Kadriu B; Nugent AC; Roiser JP; Zarate CA
    Mol Psychiatry; 2021 Jul; 26(7):3292-3301. PubMed ID: 32929215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ketamine normalizes brain activity during emotionally valenced attentional processing in depression.
    Reed JL; Nugent AC; Furey ML; Szczepanik JE; Evans JW; Zarate CA
    Neuroimage Clin; 2018; 20():92-101. PubMed ID: 30094160
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ketamine and other glutamate receptor modulators for depression in adults.
    Caddy C; Amit BH; McCloud TL; Rendell JM; Furukawa TA; McShane R; Hawton K; Cipriani A
    Cochrane Database Syst Rev; 2015 Sep; (9):CD011612. PubMed ID: 26395901
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical predictors of ketamine response in treatment-resistant major depression.
    Niciu MJ; Luckenbaugh DA; Ionescu DF; Guevara S; Machado-Vieira R; Richards EM; Brutsche NE; Nolan NM; Zarate CA
    J Clin Psychiatry; 2014 May; 75(5):e417-23. PubMed ID: 24922494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neurophysiological Changes Associated with Antidepressant Response to Ketamine Not Observed in a Negative Trial of Scopolamine in Major Depressive Disorder.
    Park L; Furey M; Nugent AC; Farmer C; Ellis J; Szczepanik J; Lener MS; Zarate CA
    Int J Neuropsychopharmacol; 2019 Jan; 22(1):10-18. PubMed ID: 30184133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of ketamine on typical and atypical depressive symptoms.
    Park LT; Luckenbaugh DA; Pennybaker SJ; Hopkins MA; Henter ID; Lener MS; Kadriu B; Ballard ED; Zarate CA
    Acta Psychiatr Scand; 2020 Nov; 142(5):394-401. PubMed ID: 32677051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dynorphin/Kappa Opioid Receptor Signaling in Preclinical Models of Alcohol, Drug, and Food Addiction.
    Karkhanis A; Holleran KM; Jones SR
    Int Rev Neurobiol; 2017; 136():53-88. PubMed ID: 29056156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.